Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3CNS 3Gastrointestinal 2Breast 2Thoracic 1Sarcoma 1Other neoplasm 1

Conditions

Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

fludarabine phosphate 3Whole-Body Irradiation 3Tacrolimus 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Melphalan 3Cyclophosphamide 3Busulfan 3fludarabine 2Specimen Handling 2Patient Reported Outcome Measures 2Methods 2Mesna 2Educational Status 2Early Intervention, Educational 2radium Ra 223 dichloride 1abemaciclib 1X-Rays 1Taxes 1Surveys and Questionnaires 1Sirolimus 1Robotic Surgical Procedures 1Resistance Training 1Radiotherapy 1Photons 1Paclitaxel 1Nivolumab 1Morphine 1Methotrexate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Photons × Other neoplasm × Clear all
NCT04090398 2026-05-13

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled
BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡